Abstract:Phospholipase A2 (PLA2) is the main constituent of snake venom. PLA2 enzymes catalyze the Ca2+ dependent hydrolysis of 2-acyl ester bonds of 3-sn-phospholipids, releasing fatty acids and lysophospholipids. Inside the body of the victim, PLA2 from snake venom induces either direct or indirect pathophysiological effects, including anticoagulant, inflammatory, neurotoxic, cardiotoxic, edematogenic, and myotoxic activities. Therefore, there is a need to find the potential inhibitors against PLA2 responsible for snakebite. In this study, we employed in silico and in vitro methods to identify the potential inhibitor against PLA2. Virtual screening and molecular docking studies were performed to find potent inhibitor against PLA2 using Traditional Chinese Medicine Database (TCM). Based on these studies, Scutellarin (TCM3290) was selected and calculated by density functional theory calculation at B3LYP/6-31G**++ level to explore the stereo-electronic features of the molecule. Further, molecular docking and DFT of Minocycline was carried out. Quantum polarized ligand docking was performed to optimize the geometry of the protein-ligand complexes. The protein-ligand complexes were subjected to molecular dynamics simulation and binding free energy calculations. The residence time of a protein-ligand complex is a critical parameter affecting natural influences in vitro. It is nonetheless a challenging errand to expect, regardless of the accessibility of incredible PC assets and a large variety of computing procedures. In this metadynamics situation, we used the conformational flooding technique to deal with rank inhibitors constructions. The systematic free energy perturbation (FEP) protocol and calculate the energy of both complexes. Finally, the selected compound of TCM3290 was studied in vitro analysis such as inhibition of PLA2 activity, hyaluronidase activity and fibrinogenolytic activity. The TCM3290 had a more binding affinity compare to Minocycline, and interacted with the key residues of TYR63 and GLY31. DFT represented the highest HOMO and LUMO energy of 0.15146 eV. MD simulation with 100 ns proved that an inhibitor binding mode is more stable inside the binding site of PLA2. In vitro analysis shows that TCM3290 significantly neutralized by PLA2. The above observations confirmed that Scutellarin (TCM3290) had a potent snake venom neutralizing capacity and could hypothetically be used for therapeutic drives of snakebite envenomation.

CHLOROQUINE A POTENTIAL DRUG CANDIDATE FOR THE MANAGEMENT OF SNAKE BITE: A STRUCTURE BASED VIRTUAL SCREENING FOR MULTI-TARGET PROFILING

Snakebite drug discovery: high-throughput screening to identify novel snake venom metalloproteinase toxin inhibitors

Structure-Based Virtual Screening, Insilico Docking, ADME Prediction, and Molecular Dynamics Studies for Identification of Potential NMT Inhibitors Against Malaria

Optimizing drug discovery for snakebite envenoming via a high-throughput phospholipase A2 screening platform

Computer-aided drug design of novel PLA2 inhibitor candidates for treatment of snakebite

A Pharmacoinformatic Study of Atrolysin Inhibitors

Combining in silico and in vitro approaches to identification of potent inhibitor against phospholipase A2 (PLA2)

Exploring the mechanism of cytisine in treating respiratory depression following venomous snake bites based on network pharmacology and molecular docking

Snake Venoms in Drug Discovery: Valuable Therapeutic Tools for Life Saving

Acetylcholine-Binding Protein Affinity Profiling of Neurotoxins in Snake Venoms with Parallel Toxin Identification

Protective effects of novel diazepinone derivatives in snake venom induced sterile inflammation in experimental animals

Enhancing snakebite management: The role of small molecule therapeutics in complementing antivenom strategies

An in-depth exploration of snake venom-derived molecules for drug discovery in advancing antiviral therapeutics

Assessing Target Specificity Of The Small Molecule Inhibitor Marimastat To Snake Venom Toxins: A Novel Application Of Thermal Proteome Profiling

Identification of Zika Virus NS2B-NS3 Protease Inhibitors by Structure-Based Virtual Screening and Drug Repurposing Approaches

Evaluation of the Inhibitory Potential of Synthetic Peptides Homologous to CDR3 Regions of a Monoclonal Antibody against Bothropic Venom Serine Proteases

The chemistry of snake venom and its medicinal potential

Exploring the antisnake venom Potential of Zingiber officinale and its bioactive compounds against Naja nigricollis venom through computational approaches and experimental validation

Varespladib in the Treatment of Snakebite Envenoming: Development History and Preclinical Evidence Supporting Advancement to Clinical Trials in Patients Bitten by Venomous Snakes

Unraveling snake venom phospholipase A2: an overview of its structure, pharmacology, and inhibitors

High-throughput virtual screening approach of natural compounds as target inhibitors of plasmepsin-II